A Neurotrophic & Nootropic Formulation with BDNF and NGF mRNA Expression Enhancement Features for the Treatment of Neurological Damage & Development Disorders BDNF NGF Neurotrophin

Updated on September 1, 2021 — Creative Commons Attribution Share-Alike 4.0

This dataset has been published on the initiative and under the responsibility of Erdal Can Alkoclar
Published on April 23, 2020 and updated on September 1, 2021

Erdal Can Alkoclar

Erdal Can Alkoclar is a Turkish Inventor, Scientist and Investor. Alkoclar is the co-founder and running president of Mas Pharmaceuticals . He is the sole inventor of 143 applied and 282 pending patents; 44 of them being in current PCT protection. Alkoclar is the rightsholder and Applicant of the…

2 datasets


Creative Commons Attribution Share-Alike 4.0


Creation date
April 23, 2020
Latest resource update
April 23, 2020




A Neurotrophic and Nootropic Formulation consisting of a Pro-Somathropic Dioscin Analouge with increased systemic duration due to prolonged half-life, a Gymnemic Acid Analouge with BDNF NGF and Neurotrophin B3 mRNA Expression Enhancing Properties. Formulation may serve as an adjuvant curative means for Neurological Development Defects along with Chronical Cerebrospinal Ailments like Dementia, Neuromascular Defects and other Neurodegenerative Disorders.

Files 2

Community resources 0

You have built a more comprehensive database than those presented here? This is the time to share it!

Reuses 0

Explore the reuses of this dataset.

Did you use this data ? Reference your work and increase your visibility.

Discussion between the owner and the community about this dataset.